Viatris is a global pharmaceutical company that produces generic, branded, and complex generic medicines across a broad range of therapeutic areas.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Louis Bacon / Moore | 53 | New buy | 2,761,054 | $43,845,538 | 0.7% |
| Larry Robbins / Glenview | 58 | Added +9% | 9,877,409 | $156,853,255 | 2.9% |
| David Einhorn / Greenlight | 44 | Added +53% | 2,773,470 | $44,042,703 | 1.1% |
| Bridgewater | 56 | Added +134% | 1,698,341 | $26,969,655 | 0.1% |
| Ancora | 40 | Trimmed -80% | 268 | $4,256 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -94% | 18,000 | $285,840 | 0.0% |
| Steve Cohen / Point72 | 76 | Trimmed -65% | 622,629 | $9,887,349 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.